Last reviewed · How we verify
NCT04442334
The European NAFLD Registry
trial in NAFLD in 10,000 participants. Currently enrolling.
31 December 2030
Quick facts
| Lead sponsor | Newcastle University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 1 May 2015 |
| Primary completion | 31 December 2030 |
| Estimated completion | 31 December 2030 |
| Sites | 37 locations across France, Italy, Finland, Netherlands, Greece, Belgium, Sweden, United Kingdom |
Conditions studied
- NAFLD — all drugs for NAFLD →
- NASH — all drugs for NASH →
- NASH - Nonalcoholic Steatohepatitis — all drugs for NASH - Nonalcoholic Steatohepatitis →
- Fibrosis, Liver — all drugs for Fibrosis, Liver →
Sponsor
Newcastle University
Who can join
Adults 18 to 100, any sex, with NAFLD or NASH. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. The ultimate goals are to better understand the drivers of interpatient variation in disease pathophysiology and severity and to utilise this information to develop and validate biomarkers that, singly or in combination, enable detection and monitoring of disease progression and/or from NAFL through NASH to fibrosis and cirrhosis.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures.
Govaere O, Hasoon M, Alexander L, Cockell S, et al · · 2023 · cited 113× · PMID 37037945 · DOI 10.1038/s42255-023-00775-1 -
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ, Govaere O, Geng D, Ratziu V, et al · · 2022 · cited 71× · PMID 35434590 · DOI 10.1016/j.jhepr.2022.100477 -
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
Johnson K, Leary PJ, Govaere O, Barter MJ, et al · · 2022 · cited 32× · PMID 35072021 · DOI 10.1016/j.jhepr.2021.100409 -
Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease.
Sen P, Govaere O, Sinioja T, McGlinchey A, et al · · 2022 · cited 23× · PMID 36065182 · DOI 10.1016/j.isci.2022.104949 -
Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information.
McTeer M, Applegate D, Mesenbrink P, Ratziu V, et al · · 2024 · cited 20× · PMID 38421999 · DOI 10.1371/journal.pone.0299487 -
Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom.
Funuyet-Salas J, Martín-Rodríguez A, Pérez-San-Gregorio MÁ, Vale L, et al · · 2024 · cited 4× · PMID 38709751 · DOI 10.1371/journal.pone.0300362 -
Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH.
Yu X, Huang C, Evers M, Liu J, et al · · 2025 · cited 2× · PMID 41004573 · DOI 10.1126/sciadv.adx2681 -
Decoding MASLD Progression: A Molecular Trajectory-Based Framework for Modelling Disease Dynamics
Kamzolas I, Koutsandreas T, Barker CG, Vathrakokoili Pournara A, et al · · 2025 · DOI 10.1101/2025.01.14.632908
Verify or expand the search:
- PubMed search for NCT04442334
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NAFLD
Currently open trials in the same condition.
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
- NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
- NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
- NCT06879236 — Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease · recruiting
- NCT06888310 — Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease · NA · recruiting
Other Newcastle University trials
Trials by the same sponsor.
- NCT07206433 — Transient Ischemic Attack (TIA) and Spoken Language · not yet recruiting
- NCT07128004 — In This Study, we Are Testing Whether Combining Two Interventions, in the Early Stages of Tinnitus, is More Effective in · NA · not yet recruiting
- NCT06551012 — Neuromuscular Fatigability in Individuals With Heart Failure · NA · not yet recruiting
- NCT07049874 — The Effect of Huel on Markers of Inflammation · NA · active not recruiting
- NCT05713474 — Micro-EMG: A Novel Multi-electrode System for Intramuscular Imaging · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04442334 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Newcastle University
- Last refreshed: 6 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04442334.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing